

CITATION REPORT

List of articles citing

Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab

DOI: 10.1016/j.jaci.2017.07.035

Journal of Allergy and Clinical Immunology, 2018, 141, 1735-17

Source: <https://exaly.com/paper-pdf/69642684/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
124	Viral infections in wheezing disorders. <i>European Respiratory Review</i> , 2018 , 27,	9.8	14
123	Targeting Antiviral Pathways for Treatment of Allergic Diseases. 2018 , 7, S54-S56		2
122	Quantitative Flow Cytometry to Measure Viral Production Using Infectious Pancreatic Necrosis Virus as a Model: A Preliminary Study. 2018 , 8, 1734		1
121	The challenge of choosing the correct biologic for the correct asthma patient. 2018 , 121, 385-386		
120	Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from Fc β RI. 2018 , 48, 2005-2014		29
119	Adrenergic Signaling at the Interface of Allergic Asthma and Viral Infections. <i>Frontiers in Immunology</i> , 2018 , 9, 736	8.4	10
118	Expression of corticosteroid-regulated genes by PBMCs in children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 940-947.e6	11.5	4
117	Immunomodulation in Pediatric Asthma. <i>Frontiers in Pediatrics</i> , 2019 , 7, 289	3.4	21
116	Rhinoviruses and the onset of asthma. 2019 , 121-136		
115	The interplay of the host, virus, and the environment. 2019 , 169-194		
114	Biologics, Clinical Context, and the Asthmas. 2019 , 7, 1437-1439		1
113	Asthma and viral infections: An intricate relationship. 2019 , 123, 352-358		28
112	Pediatric Inner-City Asthma. 2019 , 66, 967-979		5
111	Advances in asthma, asthma-COPD overlap, and related biologics in 2018. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 906-919	11.5	5
110	New insights into the utility of omalizumab. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 923-926.e51	11.5	25
109	Inner-City Asthma in Children. 2019 , 56, 248-268		27
108	The Cytokines of Asthma. 2019 , 50, 975-991		34

107	Advances in the aetiology, management, and prevention of acute asthma attacks in children. 2019 , 3, 354-364		17
106	T cells in severe childhood asthma. <i>Clinical and Experimental Allergy</i> , 2019 , 49, 564-581	4-1	5
105	Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children. 2019 , 9, e7		4
104	Preventing the development of asthma: stopping the allergic march. 2019 , 19, 161-168		11
103	Mechanisms and Management of Asthma Exacerbations. 2019 , 199, 423-432		32
102	Chronic rhinosinusitis with nasal polyps: insights into mechanisms of disease from emerging biological therapies. 2019 , 15, 59-71		14
101	Type I interferon suppresses memory Th2 cell cytokine secretion from allergic subjects. 2020 , 75, 695-698		3
100	Difficult To Treat Asthma. 2020 ,		
99	New biological treatments for asthma and skin allergies. 2020 , 75, 546-560		41
98	Summary of the Keystone Symposium "Origins of allergic disease: Microbial, epithelial and immune interactions," March 24-27, Tahoe City, California. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 1072-1081.e1	11.5	7
97	Evolving concepts in how viruses impact asthma: A Work Group Report of the Microbes in Allergy Committee of the American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 1332-1344	11.5	13
96	The use of biologic therapies for the management of pediatric asthma. 2020 , 55, 803-808		7
95	Plasmacytoid dendritic cell deficiency in neonates enhances allergic airway inflammation via reduced production of IFN- γ . 2020 , 17, 519-532		10
94	Regulation of allergic inflammation by dendritic cells. 2020 , 20, 56-63		5
93	Exacerbation-Prone Asthma. 2020 , 8, 474-482		14
92	Pityriasis rosea during omalizumab treatment for chronic spontaneous urticaria. 2020 , 33, e14356		
91	Comment on "Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab". 2020 , 59, 1417-1418		2
90	Viruses and asthma: the role of common respiratory viruses in asthma and its potential meaning for SARS-CoV-2. 2020 , 161, 83-93		15

89	Adrenergic regulation of immune cell function and inflammation. 2020 , 42, 709-717	21
88	What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?. 2020 , 33, e14068	11
87	Epithelial Cell-Associated Galectin-3 Activates Human Dendritic Cell Subtypes for Pro-Inflammatory Cytokines. <i>Frontiers in Immunology</i> , 2020 , 11, 524826	8.4 5
86	Plasmacytoid dendritic cells and asthma: a review of current knowledge. 2020 , 14, 1095-1106	1
85	Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach. 2020 , 9,	2
84	Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy. 2020 , 14, 5483-5494	4
83	Biothérapies dans l'asthme sévère de l'enfant et de l'adolescent. 2020 , 12, 2S415-2S422	
82	IgE-mediated regulation of IL-10 and type I IFN enhances rhinovirus-induced Th2 differentiation by primary human monocytes. 2020 , 50, 1550-1559	3
81	COVID-19 and Asthma: Reflection During the Pandemic. 2020 , 59, 78-88	97
80	COVID-19 in a patient with severe asthma treated with Omalizumab. 2020 , 75, 2705-2708	38
79	Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition. 2020 , 34, 211-234	10
78	Omalizumab and COVID-19 treatment: Could it help?. 2020 , 33, e13792	9
77	Immune Modulation in Asthma: Current Concepts and Future Strategies. 2020 , 99, 566-576	9
76	Respiratory Viral Infections in Exacerbation of Chronic Airway Inflammatory Diseases: Novel Mechanisms and Insights From the Upper Airway Epithelium. 2020 , 8, 99	19
75	Roles of omalizumab in various allergic diseases. 2020 , 69, 167-177	25
74	The role of atopy in asthma development and persistence. 2020 , 20, 131-137	12
73	Plasmacytoid dendritic cells suppress Th2 responses induced by epicutaneous sensitization. 2020 , 98, 215-228	1
72	Barrier dysfunction in the atopic march-how does atopic dermatitis lead to asthma in children?. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 1551-1553	11.5 9

71	Prevention of Asthma: Targets for Intervention. 2020 , 158, 913-922		13
70	Human T1 and T2 cells targeting rhinovirus and allergen coordinately promote allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 555-570	11.5	17
69	EAACI Biologicals Guidelines-Recommendations for severe asthma. 2021 , 76, 14-44		48
68	The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. 2021 , 76, 816-830		18
67	Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes. 2021 , 203, 809-821		27
66	COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases. 2021 , 60, 253-254		6
65	Early life microbial exposures and allergy risks: opportunities for prevention. 2021 , 21, 177-191		44
64	Management of allergic patients during severe acute respiratory syndrome coronavirus-2 pandemic. 2021 , 9, 115		
63	Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab. 2021 , 9,		3
62	Type I Interferon Production of Plasmacytoid Dendritic Cells under Control. 2021 , 22,		7
61	Severe asthma in the era of COVID-19: A narrative review. 2021 ,		3
60	Implications of preexisting asthma on COVID-19 pathogenesis. 2021 , 320, L880-L891		11
59	Asthma and viruses: A focus on rhinoviruses and SARS-CoV-2. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 1648-1651	11.5	1
58	Role of innate immunity and myeloid cells in susceptibility to allergic disease. 2021 , 1499, 42-53		0
57	Nasal interferon responses to community rhinovirus infections are similar in controls and children with asthma. 2021 , 126, 690-695.e1		1
56	COVID-19 in an Allergic Bronchopulmonary Aspergillosis Patient: A Case Report.. 2021 , 56, 396-398		0
55	EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. 2021 ,		0
54	Advances and highlights in asthma in 2021. 2021 , 76, 3390-3407		12

53	[Cutaneous manifestations in patients with COVID-19 with significant attention to urticaria]. 2021 , 68, 112-116		
52	Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. 2021 , 34, e15111		5
51	Hypersensitivity may be involved in severe COVID-19. <i>Clinical and Experimental Allergy</i> , 2021 ,	4.1	1
50	Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings. 2021 , 13,		5
49	Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review). 2021 , 22, 1263		1
48	Strategies for choosing a biologic for your patient with allergy or asthma. 2021 , 127, 627-637		1
47	Pediatric Inner-City Asthma. 2021 , 41, 599-611		0
46	Acute Asthma. 2022 , 278-295		
45	Childhood asthma heterogeneity at the era of precision medicine: Modulating the immune response or the microbiota for the management of asthma attack. 2020 , 179, 114046		11
44	Biologics targeting type 2 inflammation in severe asthma. 2019 , 285-303		1
43	Dynamic monitoring of immune function indexes in COVID-19 patients. 2020 , 12, 24596-24603		5
42	Critical Points on the Use of Biologics in Allergic Diseases and Asthma. 2020 , 12, 24-41		14
41	Mechanism of Rhinovirus Immunity and Asthma. <i>Frontiers in Immunology</i> , 2021 , 12, 731846	8.4	2
40	The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study. 2021 , 20, 3369-3375		5
39	IgE-mediated regulation of IL-10 and type I interferon enhances rhinovirus-induced Th2 priming by primary human monocytes.		
38	Practical Considerations in Management of Allergic Asthma. 2020 , 155-180		
37	Severe Asthma in Childhood: Special Considerations. 2020 , 265-295		
36	Immunological Diversity of Eosinophilic Diseases. 2019 , 70, 315-319		

35	Respiratory viral infections and asthma exacerbations: new opportunities of omalizumab. 2020 , 19-24		
34	Biological therapy of allergic diseases during the COVID-19 pandemic. 2020 , 17, 115-120		
33	Epithelial RIG-I inflammasome activation suppresses antiviral immunity and promotes inflammatory responses in virus-induced asthma exacerbations and COVID-19.		0
32	The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19. 2021 ,		3
31	IgE is associated with exacerbations and lung function decline in COPD.. 2022 , 23, 1		2
30	Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality.. 2022 , 1		10
29	Retrospective evaluation of patients with chronic spontaneous urticaria using omalizumab during the COVID-19 pandemic.. 2022 ,		0
28	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals - EAACI recommendations.. 2022 ,		1
27	Immunoglobulin E-Dependent Activation of Immune Cells in Rhinovirus-Induced Asthma Exacerbation.. 2022 , 3, 835748		1
26	COVID-19 Course in Allergic Asthma Patients: A Spanish Cohort Analysis.. 2022 , 15, 257-264		0
25	Can anti-IgE and anti-IL-5 monoclonal antibodies be protective against household transmission of SARS-CoV-2?. 2022 , 5, 698-701		
24	Type I Conventional Dendritic Cells Relate to Disease Severity in Virus-Induced Asthma Exacerbations.. <i>Clinical and Experimental Allergy</i> , 2022 ,	4.1	0
23	Eosinophil-mediated suppression and Anti-IL-5 enhancement of plasmacytoid dendritic cell interferon responses in asthma.. <i>Journal of Allergy and Clinical Immunology</i> , 2022 ,	11.5	1
22	Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety.. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022 , 12034754221089267	1.6	0
21	Unraveling the Relationship of Asthma and COVID-19.. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
20	Case Report: Self-Administration of Omalizumab in an Adolescent With Severe Asthma During SARS-CoV-2 Infection.. <i>Frontiers in Pediatrics</i> , 2021 , 9, 675281	3.4	1
19	Asthma and COVID-19: an update.. <i>European Respiratory Review</i> , 2021 , 30,	9.8	3
18	Innate Immune Responses by Respiratory Viruses, Including Rhinovirus, During Asthma Exacerbation. <i>Frontiers in Immunology</i> , 13,	8.4	2

17	Biologic Therapies in Pediatric Asthma. <i>Journal of Personalized Medicine</i> , 2022 , 12, 999	3.6	2
16	We need to understand why viral infections lead to acute asthma. 2022 , 60, 2200194		
15	Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody.		0
14	Covid-19 Infection in An Asthma Patient Receiving Omalizumab: Case Report.		0
13	Asthma exacerbations: the Achilles heel of asthma care. 2022 ,		0
12	Biologics for allergic and immunologic diseases. 2022 , 150, 766-777		0
11	Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN- γ production and FOXP3 + Treg generation.		0
10	Safely use of omalizumab during SARS-CoV -2 infection in patients with chronic spontaneous urticaria.		0
9	Recent developments in the immunopathology of COVID -19.		1
8	Knowledge gaps and future opportunities for biologics in childhood allergic and immunologic disorders. 2023 ,		0
7	The Effect Of COVID-19 On Patients Receiving Omalizumab Treatment. 2023 ,		0
6	Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study.		0
5	Omalizumab may protect allergic patients against COVID-19: a systematic review.. 2023 , 100741		0
4	Biologics in the treatment of asthma in children and adolescents. 2023 ,		0
3	Impact of omalizumab therapy on the course of COVID-19 in a patient with severe asthma: A case report. 1-5		0
2	Emerging role for interferons in respiratory viral infections and childhood asthma. 14,		0
1	Can Allergen Immunotherapy Improve Antiviral Immunity in Patients with Allergic Asthma?.		0